Clinical Trial Update: A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo [Phase 3]

View source ↗

Summary

Pfizer completed a 52-week Phase 3 study evaluating oral ritlecitinib in adults and adolescents with nonsegmental vitiligo (active and stable).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonsegmental Vitiligo

Drugs mentioned

• Ritlecitinib (ritlecitinib)

Snippet

Sponsor: Pfizer | Conditions: Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo | Phase 3 | Status: COMPLETED